MS Tech Secures $1.2M R&D Grant for Early Disease Detection Biosensors
MS Tech Ltd. has been awarded a $1.2M R&D grant by the Israel Innovation Authority to advance its innovative biosensor technology for early disease screening and biomarkers diagnostics, marking a significant step forward in point-of-care diagnostics.
MS Tech Ltd., a leader in nano- and biosensor technology, has recently been awarded a $1.2 million R&D grant by the Israel Innovation Authority. This grant is aimed at furthering the development of the company's Bio-Medical Division's innovative biosensor technology, which focuses on the early detection of disease biomarkers in liquid biopsies. The technology promises to revolutionize early diagnostics by providing fast, point-of-care results, a significant improvement over current laboratory-based methods that are both time-consuming and costly.
The grant recognizes MS Tech's pioneering work in the bio-convergence field, integrating biology, life sciences, engineering, and software to advance its HF-QCM sensor technologies. Doron Shalom, CEO of MS Tech, highlighted the potential of these biosensors to empower healthcare providers and patients by enabling immediate, data-driven decisions without the operational delays associated with traditional diagnostic methods.
This development is part of the LIQUIDBX Consortium's efforts to create a technological infrastructure for the early detection of diseases through advanced multi-omic sensors. These sensors analyze signals across various biological elements, supported by MS Tech's expertise in nano-sensors and collaboration with academic and industrial partners. The Israel Innovation Authority's support underscores the importance of MS Tech's contributions to scientific and technological innovation in the field of medical diagnostics and beyond.